Sign In
Buy NVCR
$16.15
+0.330 (+2.09%)
At Close: Jun 03, 2026
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?
04:29am, Thursday, 05'th Dec 2024
The life science industry recently gave folks diagnosed with pancreatic cancer the best news this group has received in a very long time. A new treatment option that significantly raises their chances
NovoCure: PANOVA-3 Data Suggests A Potential Game-Changer For Pancreatic Cancer
09:59pm, Wednesday, 04'th Dec 2024
NovoCure's TTFields therapy, combined with standard chemotherapy, significantly improves overall survival in advanced pancreatic cancer, showing a 33% improvement in two-year survival rates. Despite p
NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals
11:01am, Tuesday, 03'rd Dec 2024
Novocure stock soars 49% as the late-stage study of TTFields therapy for treating pancreatic adenocarcinoma meets the primary endpoint of overall survival.
Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields
01:10pm, Monday, 02'nd Dec 2024
Positive results achieved from phase 3 PANOVA-3 study using TTFields + Gemcitabine + Nab-paclitaxel to treat unresectable, locally advanced 1st-line pancreatic cancer patients. Multiple regulatory sub
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
10:12am, Monday, 02'nd Dec 2024
On Monday, NovoCure Ltd NVCR and Zai Lab Limited ZLAB revealed topline data from the Phase 3 PANOVA-3 trial of Tumor-Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitax
Novocure Launches 40% After Pancreatic Cancer Treatment Succeeds
08:57am, Monday, 02'nd Dec 2024
Novocure stock catapulted early Monday after the company's cancer-treating device succeeded in a study of patients with pancreatic cancer. The post Novocure Launches 40% After Pancreatic Cancer Treatm
Novocure's pancreatic cancer treatment meets main goal in late-stage study
07:17am, Monday, 02'nd Dec 2024
Novocure said on Monday its experimental therapy extended the lives of patients with a form of advanced pancreatic cancer when combined with chemotherapy, achieving the primary goal in a late-stage tr
SHANGHAI & CAMBRIDGE, Mass. & ROOT, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met it
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer.
Novocure to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 27'th Nov 2024
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to participate in upcoming investor conferences.
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure data at 2024 SNO annual meeting highlights product innovation and real-world evidence for TTFields therapy in glioblastoma.
FDA Approves Novocure's Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
07:00am, Thursday, 21'st Nov 2024
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--FDA approves Novocure's Innovative HFE transducer arrays for use with Optune Gio® for glioblastoma.
NovoCure Limited (NVCR) Q3 2024 Earnings Conference Call Transcript
11:53am, Wednesday, 30'th Oct 2024
NovoCure Limited (NASDAQ:NVCR ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Ingrid Goldberg - IR Bill Doyle - Chairman Ashley Cordova - CFO Asaf Danziger - CEO Fr
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
09:16am, Wednesday, 30'th Oct 2024
NovoCure (NVCR) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.46 per share a year ago.
Novocure Appoints Christoph Brackmann as Chief Financial Officer
07:02am, Wednesday, 30'th Oct 2024
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Appoints Christoph Brackmann as Chief Financial Officer.
